What Is The Best Approach To Hip Replacement For Different Patient Groups?

Published Sep 25, 2013
Calgary, AB, Canada - Advanced hip osteoarthritis (OA) is a common chronic condition causing severe joint pain and loss of joint function. Total hip arthroplasty (THA) is recognized as one of the most effective interventions to relieve pain and improve function, but with increasing life expectancy, people are now expected to outlive a primary THA, and require revision surgery. Therefore, other surgical approaches, like hip resurfacing arthroplasty (HRA), have been considered, particularly for younger, active patients. Researchers at the University of Calgary in Calgary, Canada compared the benefits and costs of HRA versus THA. A decision analytic model was constructed to estimate the expected cost-effectiveness of HRA compared to THA as measured by cost per quality-adjusted life year (QALY). The absolute differences between THA and HRA were small, with substantial uncertainty around the estimate of cost effectiveness. For younger patients (less than 50 years old) and male patients, however, HRA cost less and was associated with more QALYs. Total hip arthroplasty was a better option only in older patients (over 60 years old) and female patients. The results show that, on average, HRA was preferred above THA for younger and male patients, but THA is still a reasonable option if the patient or clinician prefers. The full study, “Cost-Utility of Metal-on-Metal Hip Resurfacing Compared to Conventional Total Hip Replacement in Young Active Patients with Osteoarthritis,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×